This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cardiome Announces The Addition Of Dr. Steen Juul-Möller As Medical Director, Europe


VANCOUVER, March 28, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announces the addition of Steen Juul-Möller, M.D., Ph.D./DMSc., FESC to Cardiome's management team as Medical Director, Europe.  In his capacity of Medical Director, Dr. Juul-Möller will oversee Cardiome's clinical and medical affairs activities.

Dr. Juul-Möller has held his clinical position at the Malmö University Hospital (now Skåne University Hospital) since 1980. He is a strong proponent for the rapid cardioversion of patients with recent onset atrial fibrillation (AF). Dr. Juul-Möller was responsible for changing his hospital's emergency room AF management protocol and developed an AF fast-track treatment system where patients were safely and rapidly cardioverted resulting in both patient and economic benefits. Vernakalant was regularly used in the atrial fibrillation fast-track protocol. Since BRINAVESS™ was available in Sweden, clinicians at Skåne University Hospital have used it to cardiovert over 250 recent onset atrial fibrillation patients to normal sinus rhythm achieving successful cardioversion in 70% to 80% of patients, which is almost 50% higher than what was achieved in clinical trials. He has also served on the Steering Committee of both the ACT I and ACT III pivotal Phase 3 trials for vernakalant.

"We are thrilled to have Dr. Juul-Möller join Cardiome's medical team," said Bill Hunter, M.D., Cardiome's President and CEO. "Sharing his BRINAVESS™ experience with other clinicians and decision makers such as the identification of patients who would best respond to BRINAVESS™ and the economic benefits his hospital has gained after implementing a fast-track AF protocol will be key as Cardiome assumes BRINAVESS™ commercialization activities."

In addition to clinical practice, he has concentrated his research activities on clinical cardiology. He successfully ran a large clinical project involving 94 centers in Sweden, the results of which were singularly responsible for the 1997 FDA recommendation of aspirin treatment for primary prevention of myocardial infarction in patients with stable angina (published in Lancet 1992;340:1421-1425).

For the last 10 years, Dr. Juul-Möller has directed his research towards arrhythmias and international drug development including Phase 2 through to Phase 4 clinical studies, frequently utilizing the state-of-the-art Laboratory for Ambulatory ECG Monitoring. He has had an instrumental role in creating the first Scandinavian Syncope Center, located in Malmö and developing a fast-track atrial fibrillation treatment program at his hospital.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,829.0450 +18.2570 0.38%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs